Graft-versus-host disease

Panminerva Medica

Volumn 52, Issue 2, 2010, Pages 111-124

  Choi , S ^a   Reddy, P ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Antigen presenting cells (APC); Cytokines; Minor histocompatibility (miHAs); T cells

Indexed keywords

AUTACOID; CYTOKINE;

ADAPTIVE IMMUNITY; ANIMAL; ANTIGEN PRESENTING CELL; GENETICS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-PRESENTING CELLS; CYTOKINES; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 77955433080     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (185)

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385-389
2. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation. Annu Rev Immunol. 2006.
3. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol. 2006;43:3-10.
4. Deeg HJ. How I Treat Refractory Acute GVHD. Blood. 2007.
5. Weiden PL, Floumoy N, Thomas ED, et al. Antileukemic effect of graft-verauj-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073
6. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-verms-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-1533
7. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005;105:4200-4206
8. van Bekkum DW, De Vries MJ. Radiation chimaeras. London: Logos Press; 1967.
9. Billingham RE. The biology of graft-versus-host reactions. Harvey Lec. 1966;62:21-78.
10. Korngold R, Sprent J. Purified T cell subsets and lethal graft-versus-host disease in mice. In: Gale RP, Champlin R, eds. Progress in Bone Marrow Transplant. New York: Alan R. Liss, Inc.; 1987:213-218
11. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, RJ OR. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft- v-host disease. Blood. 1986;68:770-773
12. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P. T-lympho-cyte- antigen interactions in transplant rejection. N Engl J Med. 1990; 322:510-517
13. Aosai F, Ohlen C, Ljunggren HG, et al. Different types of allospecif-ic CTL clones identified by their ability to recognize peptide loading-defective target cells. Eur J Immunol. 1991;21:2767-2774
14. Wang W, Man S, Gulden PH, Hunt DF, Engelhard VH. Class I-restrict-ed alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides. J Immunol. 1998; 160:1091-1097.
15. Man S, Salter RD, Engelhard VH. Role of endogenous peptide in human alloreactive cytotoxic T cell responses. Int Immunol. 1992;4:367-375.
16. Petersdorf EW, Malkki M. Genetics of risk factors for graft-verasus-host disease. Semin Hematol. 2006;43:11-23.
17. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197-204.
18. Petersdorf EW, Longton G, Anasetti C, al. e. Donor-recipient disparities for HLA-C genes is a risk factor for graft failure following marrow transplantation from unrelated donors. Blood. 1995;86, Suppl. 1:291a.
19. Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, McKinney SK. Association of HLA-C Disparity with Great Failure After Marrow Transplantation from Unrelated Donors. Blood. 1997;89:1818-1823
20. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104:1923-1930
21. Barker JN, Wagner JE. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer. 2003;3:526-532
22. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265-2275
23. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105:1343-1347.
24. Den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 1995;268:1476-1480
25. de Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol. 1992;149:1788-1794.
26. de Bueger M, Goulmy E. Human minor histocompatibility antigens. Transpl Immunol. 1993;1:28-38.
27. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg F. Mismatches of Minor Histocompatibility Antigens Between HLA-Identical Donors and Recipients and the Development of Graft-Versus-Host Disease After Bone Marrow Transplantation. The New England Journal of Medicine. 1996;334:281-285
28. Goulmy E. Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol. 2006;67:433-438
29. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med. 2003; 197:1279-1289
30. Malarkannan S, Shih PP, Eden PA, et al. The molecular and functional characterization of a dominant minor H antigen, H60. J Immunol. 1998;161:3501-3509
31. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-ver-jus-leukaemia effect. Nat Rev Cancer. 2004;4:371-380
32. Riddell SR, Bleakley M, Nishida T, Berger C, Warren EH. Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transpl. 2006;12:9-12.
33. Choi EY, Christianson GJ, Yoshimura Y, etal. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-vehost disease. Blood. 2002;100:4259-65.
34. Choi EY, Christianson GJ, Yoshimura Y, et al. Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide. Immunity. 2002;17:593-603.
35. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-verjuj-host disease. Nat Med. 2001 ;7:789-794
36. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-vmiw-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med. 2002;8:410-414
37. de Bueger M, Bakker A, Bontkes H, van Rood JJ, Goulmy E. High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA-identical BMT: absence of correlation with GVHD. Bone Marrow Transpl. 1993; 11.
38. Miller JS, SoignierY, Panoskaltsis-Mortari A, etal. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105:3051-3057
39. Miller JS, Cooley S, Parham P, et al. Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007.
40. Velardi A, Ruggeri L, Alessandro, Moretta, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 2002;23:438-444
41. Petersdorf EW. Immunogenomics of unrelated hematopoietic cell transplantation. Curr Opin Immunol. 2006;18:559-564
42. Hsu KC, Gooley T, Malkki M, et al. KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy. Biol Blood Marrow Transpl. 2006;12:828-836
43. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
44. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002; 100:3825-3827
45. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878-4884
46. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964-2968
47. Cavet J, Middleton PO, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999;94:3941-3946
48. Dickinson AM, Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol. 2005;17:517-525 (Pubitemid 41207956)
49. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-veraui-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003;349:2201-2210
50. Mullighan CG, Bardy PG. New directions in the genomics of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2007;13:127-144
51. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98:1594-1600.
52. Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood. 2006;107:4189-4193
53. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449:819-826
54. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882-1891
55. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754-2759
56. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213
57. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incom-patible transplanted SCID mice. Blood. 1994;83:2360-2367
58. Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T cell reconstitution and attenuates the severity of graft versus host disease. Blood. 2009.
59. Taylor PA, Ehrhardt MJ, Lees CJ, et al. TLR agonists regulate allore-sponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood. 2008; 112:3508-3516
60. Chakraverty R, Flutter B, Fallah-Arani F, et al. The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells. J Immunol. 2008;181:6820-6828
61. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol. 2003;3:371-382
62. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood. 2004;104:889-894
63. Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 2009;323:1722-1725
64. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252
65. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415
66. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med. 2005; 11:1244-9.
67. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987-992
68. Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreacti ve T cells prevents skin graft-versus-host disease. Nat Med. 2004; 10:510-517
69. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340-352
70. Munz C. Enhancing immunity through autophagy. Annu Rev Immunol. 2009;27:423-449
71. Hadeiba H, Sato T, Habtezion A, Oderup C, Pan J, Butcher EC. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat Immunol. 2008;9:1253-1260
72. Koyama M, Hashimoto D, Aoyama K, et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graii-versus-host disease as antigen-presenting cells. Blood. 2009; 113:2088-2095
73. Banovic T, Markey KA, Kuns RD, et al. Graft-versus-host disease prevents the maturation of plasmacytoid dendritic cells. J Immunol. 2009;182:912-920
74. Haniffa M, Ginhoux F, Wang XN, et al. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J Exp Med. 2009;206:371-385.
75. Appleman U, Boussiotis VA. T cell anergy and costimulation. Immunol Rev. 2003;192:161-180
76. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116-126
77. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev. 2009;229:271-293
78. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA. Ligation of 4-1BB (CDw 137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol. 2001;166:3174-3183
79. Blazar BR, Levy RB, Mak TW, et al. CD30/CD30 ligand (CD 153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol. 2004;173:2933-2941
80. Blazar BR, Sharpe AH, Chen Al, et al. Ligation of OX40 (CD 134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood. 2003;101:3741-3748
81. Blazar BR, Taylor PA, Linsley PS, Vallera DA. in vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-vesus-host disease across the major histocompatibility complex barrier in mice. Blood. 1994;83:3815-3825
82. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Blockade of CD40 ligand-CD40 interaction impairs CD4+T cell-mediated allore-activity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 1997;158:29-39.
83. Hubbard VM, Eng JM, Ramirez-Montagut T, et al. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. Blood. 2005;106:3285-3292
84. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171:1272-1277
85. Morris ES, MacDonald KP, Kuns RD, et al. Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. Nat Med. 2009;15:436-441
86. Ringden O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukmia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22:416-423
87. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A. 2004;101:3921-3926
88. Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest. 2008;118:2562-2573
89. Sun Y, Chin YE, Weisiger E, et al. Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol. 2009;182:5899-5903
90. Wilson J, Cullup H, Lourie R, et al. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med. 2009;206:387-398
91. Maeda Y, Reddy P, Lowler KP, Liu C, Bishop DK, Ferrara JL. Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood. 2005;106:749-755
92. Asai O, Longo DL, Tian Z, Hornung RL, Taub DD, Ruscetti FW. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;101:1835-1842
93. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killerT cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97:2923-2931
94. Nishimura R, Baker J, Beilhack A, et al. in vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008; 112:2563-2574
95. Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood. 2009; 113:4458-4467
96. Pillai AB, George TI, Dun S, Teo P, Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol. 2007;178:6242-6251
97. Morris ES, MacDonald KP, Rowe V, et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest. 2005; 115:3093-3103
98. Kuns RD, Morris ES, Macdonald KP, et al. Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration. Blood. 2009; 113:5999-6010.
99. Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood. 2006;108:2485-2492
100. Michonneau D, Peffault de Latour R, Porcher R, et al. Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants. Br J Haematol. 2009;145:107-114
101. Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood. 2008;111:2919-2928
102. Anderson BE, Taylor PA, McNiff JM, etal. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood. 2008; 111:5242-5251
103. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol. 2006;90:133-173
104. Spierings E, Drabbels J, Hendriks M, et al. A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications. PLoS ONE. 2006; 1 :e42.
105. Friedman TM, Goldgirsh K, Berger SA, et al. Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation. Blood. 2008;112:3517-3525
106. Anderson BE, McNiff J, Yan J, et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112:101-108.
107. Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood. 2004;103:1534-1541
108. Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood. 2005;105:2220-2226
109. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004;104:3804-3812
110. Zheng H, Matte-Martone C, Li H, et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood. 2008; 111:2476-2484
111. Miller JS, Weisdorf DJ, Burns LJ, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood. 2007;110:2761-2763
112. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol. 2005;174:3051-3058 (Pubitemid 40279726)
113. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nature medicine. 2005;11:1299.
114. Dutt S, Tseng D, Ermann J, et al. Naive and Memory T Cells Induce Different Types of Graft-versus-Host Disease. J Immunol. 2007;179:6547-6554
115. Blazar BR, Taylor PA. Regulatory T cells. Biol Blood Marrow Transpl. 2005;11:46-49
116. Cohen JL, Boyer O. The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Qirr Opin Immunol. 2006;18:580-585
117. Roncarolo MG. The Role of Interleukin-10 in Transplantation and GVHD. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-versus-Host Disease (ed 2nd). New York: Marcel Dekker, Inc.; 1997:693-715.
118. Young KJ, DuTemple B, Phillips MJ, Zhang L. Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol. 2003;171:134-141 (Pubitemid 36745281)
119. Zeng D, Lewis D, Dejbakhsh-Jones S, etal. Bone marrow NKl.l(-) and NK 1.1 (+) T cells reciprocally regulate acute graft versus host disease. J Exp Med. 1999;189:1073-1081
120. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol. 2007;8:457-462
121. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401-406
122. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1150
123. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389-399
124. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transpl. 2003;9:243-256
125. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493-3539
126. Coghill JM, Carlson MJ, Moran TP, Serody JS. The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. Leuk Lymphoma. 2008;49:1860-1919
127. Nguyen VH, Shashidhar S, Chang DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008; 111:945-953
128. Dieckmann D, Plottner H, Berchtold S, BergerT, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001; 193:1303-1310.
129. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285-1294
130. Hoffmann P, Boeld TJ, Eder R, et al. Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transpl. 2006;12:267-274
131. Zom E, Mohseni M, Kim H, et al. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:382-388
132. MacDonald KP, Rowe V, Clouston AD, et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol. 2005;174:1841-1850
133. Ferrara JL, Krenger W. Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines. Transf Med Rev. 1998; 12:1-17.
134. Ferrara JLM. The cytokine storm of acute graft-versus host disease. Haematol Rev. 1994;8:27.
135. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003;21:149-161
136. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase HI study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303-2314
137. Liu EH, Siegel RM, Harlan DM, O'Shea JJ. T cell-directed therapies: lessons learned and future prospects. Nat Immunol. 2007;8:25-30.
138. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108:390-399.
139. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005;11:1238-1243
140. Liston A, Rudensky AY. Thymic development and peripheral homeostasis of regulatory T cells. Curr Opin Immunol. 2007; 19:176-185
141. Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007;445:771-775
142. Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest. 1998;102:2126-2135.
143. Yang YG, Qi J, Wang MG, Sykes M. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood. 2002;99:4207-4215
144. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med. 2001;194:1433-1440 (Pubitemid 33081518)
145. Burman AC, BanovicTD, Kuns RD, etal. IFN{gamma) differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood. 2007.
146. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood. 1994;84:3540-3549
147. Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995; 155:585-593
148. Pan L, Delmonte J, Jalonen C, Ferrara J. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T-lym-phocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422-4429
149. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-verssus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 1998; 102:115-123
150. Reddy P, Teshima T, Hildebrandt G, et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 2003;101:2877-2885
151. Foley JE, Jung U, Miera A, et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol. 2005;175:5732-5743
152. Jung U, Foley JE, Erdmann AA, et al. Ex vivo rapamycin generates Thl/Tcl orTh2/Tc2 effectorT cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin herapy. Biol Blood Marrow Transpl. 2006; 12:905-918
153. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma. 2000;38:221-234
154. Tawara I, Maeda Y, Sun Y, et al. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-versus-host disease. Exp Hematol. 2008;36:988-996
155. NikolicB,LeeS, BransonR.GrusbyM,SykesM.Thl andTh2mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000;105:1289-1298
156. Yi T, Zhao D, Lin CL, et al. Absence of donor Thl7 leads to augmented Thl differentiation and exacerbated acute graft-versus-host disease. Blood. 2008; 112:2101-2110
157. Kappel LW, Goldberg GL, King CG, et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood. 2009; 113:945-952
158. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. in vitro-differentiatedTH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009; 113:1365-1374
159. Cyster JG. Chemokines, sphingosine-1 -phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005;23:127-159.
160. Krenger W, Hollander GA. The immunopathology of thymic GVHD. Semin Immunopathol. 2008;30:439-456
161. Ribeiro RM, Perelson AS. Determining thymic output quantitatively: using models to interpret experimental T-cell receptor excision circle (TREC) data. Immunol Rev. 2007;216:21-34.
162. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001;97:1458-1466
163. Clave E, Busson M, Douay C, et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood. 2009;113:6477-6484
164. Sackstein R. A revision of Billingham's tenets: The central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transpl. 2006; 12:2-8.
165. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood. 2005;105:4191-4199.
166. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol. 2003;31:897-902.
167. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest. 1999;104:49-57.
168. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, et al. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol. 2004; 173:845-854
169. Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood. 2005;106:3300-3307
170. Waldman E, Lu SX, Hubbard VM, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006; 107:1703-1711
171. Mapara MY, Leng C, Kim YM, et al. Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol Blood Marrow Transpl. 2006; 12:623-634
172. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528-530
173. van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol. 2002;2:273-281
174. Brown GR, Lee E, Thiele DL. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J->C57BL/6J x bml2)Fl mice. J Immunol. 2002;168:3065-3071
175. Brown GR, Lee EL, El-Hayek J, Kintner K, Luck C. IL-12-indepen-dent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. J Immunol. 2005;174:4688-4695
176. Sato K, Nakaoka T, Yamashita N, et al. TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol. 2005;174:4025-4033
177. Schmaltz C, Alpdogan O, Kappel BJ, et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med. 2002;8:1433-1437
178. Xu Y, Flies AS, Flies DB, et al. Selective targeting of the LIGHT-HVEM co-stimulatory system for the treatment of graft-versus-host disease. Blood. 2006.
179. Zimmerman Z, Shatry A, Deyev V, et al. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Biol Blood Marrow Transpl. 2005;11:576-586
180. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft versus host disease. J Exp Med. 1987;166:1280-1289
181. Abhyankar S, Gilliland DG, Ferrara JL. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation. 1993;56: 1518-1523
182. Krenger W, Falzarano G, Delmonte J, Jr., Snyder KM, Byon JC, Ferrara JL. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood. 1996;88:1113-1121
183. Nestel FP, Greene RN, Kichian K, Ponka P, Lapp WS. Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. Blood. 2000;96:1836-1843
184. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964-2968
185. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170